Novel treatments for depression

Depression affects mood, energy, sleep and overall quality of life. Many people benefit from established treatments such as antidepressant medication and psychological therapies, but these approaches are not effective for everyone.

In recent years, advances in research have led to the development of novel treatments for depression, offering additional options for those who continue to experience symptoms.

Why are new treatments for depression needed?

Traditional antidepressants primarily target brain chemicals such as serotonin and noradrenaline. Although these medications can be effective, approximately one in three people continue to experience symptoms despite trying multiple treatments.

This is often described as treatment-resistant depression. Newer therapies aim to work differently, targeting brain networks, neuroplasticity, inflammation or psychological processes more directly.

Ketamine and esketamine for depression

Ketamine and esketamine act on the brain’s glutamate system, which plays a key role in mood regulation and learning. Unlike conventional antidepressants, these treatments can produce rapid improvements in depressive symptoms, sometimes within hours or days.

Who may benefit?

Esketamine nasal spray is approved in the UK for some individuals with treatment-resistant depression. It is prescribed by specialists and administered in a closely monitored clinical setting, alongside an oral antidepressant.

Psychedelic-assisted therapy for depression

Research into psychedelic-assisted therapy, particularly using psilocybin, has increased significantly in recent years.

A therapy-led approach

In clinical trials, psilocybin is administered in a controlled medical environment with structured psychological support before, during and after treatment. Early evidence suggests it may help some people by increasing emotional insight and psychological flexibility.

Current availability

At present, psychedelic therapy for depression is not routinely available through the NHS. Ongoing clinical trials will determine its future role in mainstream care.

Brain stimulation therapies for depression

These treatments target specific areas of the brain to help regulate mood and can be considered when other therapies have not provided sufficient benefit.

Repetitive transcranial magnetic stimulation

Repetitive transcranial magnetic stimulation, often shortened to rTMS, uses targeted magnetic pulses to stimulate brain regions involved in mood regulation. It is non-invasive, does not require anaesthesia and is generally well tolerated.

Deep brain stimulation

Deep brain stimulation involves surgically implanting electrodes into specific brain areas. It remains an experimental treatment for severe depression and is currently limited to specialist research settings.

Novel treatments for depression are broadening understanding of the condition and expanding therapeutic options, particularly for those who have not benefited from standard approaches. While not all treatments are suitable or widely available, they reflect a move towards more personalised mental healthcare.